SenzaGen AB (ST:SENZA) — Market Cap & Net Worth
Market Cap & Net Worth: SenzaGen AB (SENZA)
SenzaGen AB (ST:SENZA) has a market capitalization of $17.46 Million (Skr162.27 Million) as of June 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #25553 globally and #528 in its home market, demonstrating a -1.43% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SenzaGen AB's stock price Skr5.50 by its total outstanding shares 29504026 (29.50 Million). Review SenzaGen AB total liabilities to assess the company's total debt and financial obligations.
SenzaGen AB Market Cap History: 2017 to 2026
SenzaGen AB's market capitalization history from 2017 to 2026. Data shows change from $107.95 Million to $17.46 Million (-21.02% CAGR).
Index Memberships
SenzaGen AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.84 Billion | 0.11% | #125 of 281 |
Weight: SenzaGen AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
SenzaGen AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SenzaGen AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.38x
SenzaGen AB's market cap is 0.38 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $107.95 Million | $1.15 Million | -$12.99 Million | 93.63x | N/A |
| 2018 | $103.13 Million | $2.00 Million | -$16.09 Million | 51.64x | N/A |
| 2019 | $59.25 Million | $2.72 Million | -$50.24 Million | 21.75x | N/A |
| 2020 | $41.59 Million | $7.96 Million | -$27.32 Million | 5.23x | N/A |
| 2021 | $31.75 Million | $15.42 Million | -$31.35 Million | 2.06x | N/A |
| 2022 | $38.26 Million | $41.77 Million | -$24.91 Million | 0.92x | N/A |
| 2023 | $23.11 Million | $49.87 Million | -$22.10 Million | 0.46x | N/A |
| 2024 | $21.91 Million | $57.70 Million | -$17.85 Million | 0.38x | N/A |
Competitor Companies of SENZA by Market Capitalization
Companies near SenzaGen AB in the global market cap rankings as of June 19, 2026.
Key companies related to SenzaGen AB by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #131 globally with a market cap of $174.56 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #189 globally with a market cap of $125.14 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #621 globally with a market cap of $44.18 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #664 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #131 | Thermo Fisher Scientific Inc | NYSE:TMO | $174.56 Billion | $464.61 |
| #189 | Danaher Corporation | NYSE:DHR | $125.14 Billion | $177.17 |
| #621 | IDEXX Laboratories Inc | NASDAQ:IDXX | $44.18 Billion | $562.09 |
| #664 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
SenzaGen AB Historical Marketcap From 2017 to 2026
Between 2017 and today, SenzaGen AB's market cap moved from $107.95 Million to $ 17.46 Million, with a yearly change of -21.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr17.46 Million | -9.54% |
| 2025 | Skr19.30 Million | -11.88% |
| 2024 | Skr21.91 Million | -5.22% |
| 2023 | Skr23.11 Million | -39.59% |
| 2022 | Skr38.26 Million | +20.50% |
| 2021 | Skr31.75 Million | -23.66% |
| 2020 | Skr41.59 Million | -29.80% |
| 2019 | Skr59.25 Million | -42.55% |
| 2018 | Skr103.13 Million | -4.47% |
| 2017 | Skr107.95 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of SenzaGen AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $17.46 Million USD |
| MoneyControl | $17.46 Million USD |
| MarketWatch | $17.46 Million USD |
| marketcap.company | $17.46 Million USD |
| Reuters | $17.46 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SenzaGen AB
SenzaGen AB provides non-animal tests for assessing allergenicity. The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; and GARD air, a respiratory sensitization assessment. It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, and skin sensitization medical device services; advisory services for medical devices;… Read more